A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma

What is the purpose of this trial?

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.



Acerta Pharma, BV

Start Date: 12/20/2017

End Date: 10/01/2022

Last Updated: 02/22/2018

Study HIC#: 2000021105